Retrospective Evaluation of Pediatric Brucella Patients Followed and Family Screening with Household Members for Brucella Infection

Pediatrik Brusella Olgularının Retrospektif Değerlendirilmesi ve Yakın Temaslı Aile Bireylerinde Brusella Enfeksiyonu Taraması

Fevzi Çağlar Özcanaslan¹(ID), Ümmühan Çay²(ID), Özlem Özgür Gündeşlioğlu²(ID), İllker Ünal³(ID), Emine Kocabaş²(ID)

¹ Division of Pediatric Neurology, Department of Pediatrics, Mersin University Faculty of Medicine, Mersin, Turkey
² Division of Pediatric Infection, Çukurova University Faculty of Medicine, Adana, Turkey
³ Department of Biostatistic, Çukurova University Faculty of Medicine, Adana, Turkey

Abstract

Objective: In this study we aimed to analyse demographic and clinic properties, laboratory findings and efficiency of medical therapy of pediatric patients with Brucellosis followed at Çukurova University Faculty of Medicine, Pediatric Infection Diseases out patient and in patient clinic, and screening the households members of acute patients for occurring Brucella Infection.

Material and Methods: The files of 65 children with brucellosis were retrospectively reviewed for six years. Brucella scans, demographic and clinical characteristics of all patients included in the study and those with family screening were recorded. Tube agglutination test for brucella was studied in the sera of all patients and close family members. Serum tube agglutination test of all patients and household members were analysed at Çukurova University Faculty of Medicine Central Laboratory. The statistical analysis were made at Çukurova University Faculty of Medicine, Department of Biostatistic.

Results: Thirty-eight of 65 patients (58.5%) were male and 27 of 65 patients (41.5%) were female. Patients’ age range was 9-198 months and mean age was 104 months. Elapsed time until brucella diagnosis was range between 3-150 days. The most common symptom was fever that observed in 81.5% patients. The most common physical examination finding was hepatosplenomegaly that observed in 20% patients. There was statistically significant decrease between seropositivity of brucella, ESH and CRP values before and after the treatment (p< 0.001). Success rate of triple antibiot-
ics treatment regimen during six weeks was 96.8%. Seropositivity rate was found 18.2% in the household members of acute patients.

**Conclusion:** In our region, evaluating family history for brucella, raw milk and/or dairy products consumption in patients admitting to hospital with fever, arthralgia, hepatosplenomegaly, pancytopenia or bicytopenia has an important value for early diagnosis. Clinical and serological examination of close family members of patients with brucellosis may allow early diagnosis and treatment of possible close contact cases. Doing this study in a large segment of the population at risk in endemic countries for brucella like our country is critically important to provide early diagnosis and allow for early treatment.

**Keywords:** Brucella, family screening, child, laboratory findings

---

**Introduction**

Brucellosis is a substantive public health problem, which is commonly seen in the world and endemic in developing countries such as ours (1). Findings and symptoms of the disease may be diverse. It may show clinical diversity ranging from serology positivity detected coincidentally to severe clinical manifestations such as endocarditis and neurobrucellosis.

Zoonotic diseases like brucellosis may be common in individuals sharing the same socioeconomic conditions. Studies have shown that concurrent brucella infection may occur without symptoms and findings in family members consuming the same dairy products and sharing the same environment with index cases of brucellosis (2,3). Therefore, close-contact screening based on acute brucella cases found in a region may enable the detection of new cases.

In this study, it was aimed to evaluate the clinical and epidemiological characteristics and laboratory findings of brucellosis and the efficiency of the treatment administered, and to assess close-contact family members in terms of brucella infection development.

**Materials and Methods**

In this study, the files of 65 pediatric cases diagnosed with brucellosis and followed in the ward and/or polyclinic of Medical Faculty Division of Pediatric Infection during a period of six years were retrospectively evaluated. Diagnosis in all patients was made by standard tube agglutination (STA) and/or positive blood culture in the presence of clinical symptoms and findings such as fever, arthralgia, hepatosplenomegaly, and lymphadenopathy. Patients’ demographics, clinical values, laboratory findings, and the treatment administered, consumption of raw milk and dairy products, history of husbandry, and information on brucella infection of close-contact family members were recorded.

Approval was obtained from the Ethics Board of the Faculty of Medicine. Serum samples taken from all patients were analyzed with STA test at the center laboratory of Çukurova University Faculty of Medicine. Brucellosis diagnosis was made in patients and family members with a serum STA value of ≥1/160. For Brucella hepatitis, a 1.5 fold higher value (≥60 U/ml) compared to the reference value of alanine aminotranspherase (ALT) was predicated on. Brucella in the cerebrospinal fluid (CSF) was determined by tube agglutination test and/or positive CSF culture.

The treatment regimen included rifampisin (10 mg/kg/dose, oral 2 doses) and co-trimoxazole (10 mg/kg/day, oral 2 doses) for 42 days, and gentamycin (5 mg/kg/dose, single dose IM) for 5–7 days for children aged ≤8 years, and rifampisin (10 mg/kg/dose, oral 2 doses) and doxycycline (4 mg/kg/day, oral 2 doses) for 42 days and gentamycin (5 mg/kg/day, single dose IM) for 5–7 days for children aged >8 years.

**Statistical Evaluation**

PAWS program was used for data analysis. Categorical variables were expressed as number and percentage and continuous variables as mean and standard deviation (median and min-max when necessary).

Wilcoxon Signed rank test was used in the comparison of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) pre- and post- treatment, and McNemar test was used to compare seropositivity rates. Statistical significance in all tests was set at p < 0.05.

**Results**

Table 1 shows the demographic and clinical characteristics of 65 brucellosis patients. Fifty-eight point five percent of the patients were boys and 41.5% were girls. While 32% of the patients lived in the countryside, 67.7% lived in the city. Family or close circle of 38.5% of the patients had a history of active brucella infection. The duration between onset of complaints and brucellosis diagnosis of the patients was between 3 and 150 days, with a mean of 21 days. Twenty-two patients (33.8%) fed farm animals. Ninety-two point three percent of the patients had a history of raw milk and/or dairy product consumption.

Symptoms and clinical findings of the patients at the time of presentation were shown in Table 2. The most frequent
symptom was fever with 81.5%, followed by fatigue, loss of appetite, night sweating, and joint pain. The most common physical examination finding was hepatosplenomegaly with 20%, followed by joint tenderness, lymphadenopathy, and limited joint movement.

Leucocyte count, mean platelet count, and mean Hct value at the time of diagnosis in 65 patients were found respectively as 2.1-18.9 x10^3/mm^3, 2.4 ± 1.25 x 10^5/mm^3, and 32.72 ± 5.41%. Serum aspartate aminotransferase (AST) and ALT values were studied in all 65 patients. In 24 (37.5%) patients, transaminase value was found higher than the reference value. Brucella hepatitis was determined in 15 (23.5%) of the cases. AST and ALT values in one of the patients were found as 1918 U/L and 941 U/L, respectively. AST and ALT values of this patient returned to normal during the course of the treatment. ESH value was higher than 20 mm/h in 43% of the patients. CRP value of the patients was higher than the reference value in 50.8% of the patients. Growth was detected in 22 (47.8%) of 46 patients from whom blood culture was taken. All of the growing microorganism were B. melitensis (Table 3). Abdominal ultrasonography (USG) was performed in 27 of 65 patients (41.5%). Hepatomegaly was detected in three (11.1%) patients, splenomegaly in 10 (37%) and hepatosplenomegaly in 9 (33.3%) patients.

### Table 1. Demographics of pediatric cases with brucella

| Characteristics                      | n = 65          |
|--------------------------------------|-----------------|
| Age (month)                          | 103.8 ± 52.9    |
| Mean ± SD                            | 104             |
| Median                               | 9-198           |
| Range (min-max)                      |                 |
| Sex                                  |                 |
| Male, n (%)                          | 38 (58.5)       |
| Female, n (%)                        | 27 (41.5)       |
| Living space                         |                 |
| Countryside, n (%)                   | 21 (32.3)       |
| City, n (%)                          | 44 (67.7)       |
| Time passed until diagnosis (day)    |                 |
| Mean ± SD                            | 30.68 ± 26.65   |
| Median                               | 21              |
| Range (min-max)                      | 3-150           |
| Active brucella history in the family or immediate circle (+) n (%) | 25 (38.5) |
| History of husbandry (+) n (%)       | 22 (33.8)       |
| History of raw milk and dairy products consumption (+) n (%) | 60 (92.3) |

### Table 2. Clinical characteristics of pediatric patients diagnosed with brucella

| Symptoms                          | n = 65          |
|-----------------------------------|-----------------|
| Fever (+), n (%)                  | 53 (81.5)       |
| Duration of fever before diagnosis (day) |                 |
| Mean ± SD                         | 27.64 ± 22      |
| Median                            | 20              |
| Range (min-max)                   | 3-90            |
| Fatigue (+), n (%)                | 50 (76.9)       |
| Loss of appetite (+), n (%)       | 46 (70.8)       |
| Night sweating (+), n (%)         | 30 (46.2)       |
| Weight loss (+), n (%)            | 22 (33.8)       |
| Joint pain (+), n (%)             | 25 (38.5)       |
| Hepatitis (+), n (%)              | 2 (3.1)         |
| Diplopia (+), n (%)               | 2 (3.1)         |
| Findings                          |                 |
| Fever ≥38°C (+), n (%)            | 4 (6.2)         |
| Lymphadenopathy (+), n (%)        | 8 (12.3)        |
| Hepatosplenomegaly (+), n (%)     | 13 (20)         |
| Joint tenderness (+), n (%)       | 12 (18.5)       |
| Joint swelling (+), n (%)         | 5 (7.7)         |
| Temperature rise on the joint (+), n (%) | 3 (4.6)         |
| Limited joint movement (+), n (%) | 6 (9.2)         |
| Atypical walk (+), n (%)          | 1 (1.5)         |
| Deviation of the eye inwards, n (%) | 1 (1.5)         |

### Table 3. Laboratory findings of the pediatric patients diagnosed with brucella at the time of diagnosis

| Laboratory characteristics          | n = 65          |
|-------------------------------------|-----------------|
| Leucocyte count (x10^3/mm^3)        |                 |
| Mean ± SD                           | 7 ± 3.04        |
| Median                              | 7.1             |
| Range (min-max)                     | 2.1-18.9        |
| Platelet count (x10^5/mm^3)         |                 |
| Mean ± SD                           | 2.4 ± 1.25      |
| Median                              | 2.3             |
| Range (min-max)                     | 0.05-6.2        |
| Hct (%)                             |                 |
| Mean ± SD                           | 32.72 ± 5.41    |
| Median                              | 33.3            |
| Range (min-max)                     | 15-46           |
| ESH (mm/h)                          |                 |
| <20, n (%)                          | 37 (57)         |
| ≥20, n (%)                          | 28 (43)         |
| CRP (mg/L)                          |                 |
| <8.2, n (%)                         | 31 (49.2)       |
| ≥8.2, n (%)                         | 32 (50.8)       |
| ALT (U/L)                           |                 |
| <40, n (%)                          | 40 (62.5)       |
| 40-60, n (%)                        | 9 (14)          |
| ≥60, n (%)                          | 15 (23.5)       |
| Growth in blood culture (+)         |                 |
| n = 46                              | 22 (47.8)       |
Leucocyte, platelet, and hct values were evaluated according to age-specific normal values in complete blood count. Most commonly anemia followed by neutropenia, thrombocytopenia, pancytopenia, thrombocytosis, leukocytosis were detected in all patients, and hematologic involvement rate was found as 29.2% (Table 4).

Treatments of the 62 patients out of 65 were administered as stated in the Material and Methods section. Treatment combinations used in the treatment of brucellosis patients were rifampisin + co-trimoxazole + gentamycin in 44.6% of the patients, rifampisin + co-trimoxazole in 1.5% and rifampisin + doxycycline + gentamycin in 49.3%. Only the treatment of 3 patients was regulated individually due to side effects of the drugs.

Brucella STA test seropositivity rates (STA≥1/160) and mean ESH and CRP values were assessed before and after treatment (Table 5). While seropositivity was detected in 63 of the 65 patients (96.9%), following treatment, seropositivity was found in 23 of 54 patients (42.6%) (p< 0.001). While mean ESH was 22.17 ± 20.11 mm/h in 65 patients before treatment, it was 7.96 ± 7.56 mm/h in 54 patients after treatment (p< 0.001). While mean CRP was 16.53 ± 19.4 mg/dl in 65 patients before treatment, it was 4.79 ± 4.51 mg/dl after treatment (p< 0.001). To conclude, a statistically significant decrease was established in ESH, CRP values and STA test seropositivity rates before and after treatment.

There was a total of 307 close-contact family members of 65 cases. In 16 (24.6%) of the 99 (32.2%) family members of 24 index patients (36.9%) who were screened, similar complaints like fever, joint pain, and fatigue were observed at the time of diagnosis. Seropositivity (STA≥ 1/160) was detected in 18 (18.2%) close-contact family members of 9 cases.

**Discussion**

Brucellosis is an important cause of economic loss and public health problem in many developing countries and one of the zoonotic diseases seen widely in the world with a high morbidity for both humans and animals (1,4). The disease in our country is seen in both sexes and at every age. Age range has been found as six months to 16 years in studies involving the pediatric age group (5-10). In a study by Buzgan et al. comprising 1028 cases, it has been reported that 53.42% of the cases were between 13-34 years of age (6). Age range in our study was found as nine months to 16.5 years, and these values were consistent with the age range found in other studies including pediatric cases.

Most commonly, mode of transmission is through cheese, custard and butter made using raw milk. In places where milk is consumed by being pasteurized first, transmission through direct contact is at the forefront compared to oral transmission (1). In our study, raw milk and/or use of unpasteurized dairy products was detected in 92.3% of our cases. It is seen that studies have reported a rate between 63.6% and 94.6% for raw milk and/or unpasteurized dairy products consumption (6-11). Brucella infection may be transmitted from both the newborn and infant congenitally and moreover, breastmilk may be infected through the consumption of infected animal products and inhalation of infected particles. In our study, we detected that the mode of transmission in our 9-month-old case was through the consumption of unpasteurized animal products.

Diagnosis and treatment may be delayed in brucellosis since its symptoms and findings can be easily confused with those of other diseases. In our study, the most common symptom was fever, followed by fatigue, loss of appetite, night sweating, and joint pain. Arthralgia and hepatosplenomegaly were most commonly detected on physical examination. Similar results have been reported in case series in the literature (6,7,9,11). Mean time of diagnosis between the onset of complaints and brucellosis diagnosis was 21 days, and this duration can extend to 150 days. Diversity of clinical symptoms,

| Hematologic characteristics | n= 65  |
|-----------------------------|--------|
| Hematologic involvement rate (%) (29.2) |        |
| Anemia, n (%) | 40 (61.5) |
| Leukocytosis, n (%) | 3 (4.6) |
| Leucopenia, n (%) | 14 (21.5) |
| Thrombocytopenia, n (%) | 14 (21.5) |
| Thrombocytosis, n (%) | 5 (7.7) |
| Pansitopenia, n (%) | 8 (12.3) |

| Comparison of ESH, CRP and STA values of the pediatric patients diagnosed with brucella before and after treatment |
|-------------------------------------------------|
| Before treatment | After treatment | p     |
| ESH (mm/h) Mean ± SD | 22.17 ± 20.11 | 7.96 ± 7.56 | <0.001 |
| CRP (mg/dl) Mean ± SD | 16.53 ± 19.4 | 4.79 ± 4.51 | <0.001 |
| STA≥ 1/160 n (%) | 63 (96.9) | 23 (42.6) | <0.001 |

**Table 4.** Hematologic findings of the pediatric patients diagnosed with brucella at the time of diagnosis

**Table 5.** Comparison of ESH, CRP and STA values of the pediatric patients diagnosed with brucella before and after treatment
and the nonspecific and mostly asymptomatic nature of the diseases lead to late diagnoses. Late diagnosis in brucellosis may cause a serious increase in morbidity and mortality. Family history, farm animal breeding, consumption of unpasteurized milk and dairy products must be questioned and brucellosis must be considered in patients with clinical symptoms including fever, arthralgia, hepatosplenomegaly, bicytopenia, and pancytopenia.

Routine laboratory investigations in brucellosis are usually not specific to the disease. In a study investigating 48 brucellosis cases with hematologic findings in our country, anemia, leucopenia, thrombocytopenia, and pancytopenia were detected at a rate of 81%, 58%, 46%, and 21%, respectively (12). In a study consisting 97 pediatric cases, anemia was detected at a rate of 52.6%, leucopenia 9.3%, leukocytosis 11.3%, thrombocytosis 10.3%, and pancytopenia 6.2% (10). In our study, hematologic involvement was 29.2%, anemia 61.5%, leucopenia 21.5%, leukocytosis 4.6%, thrombocytopenia 21.5%, thrombocytosis 7.7%, and pancytopenia 7.7%, all consistent with the literature. Acute phase reactants are not diagnostic but supportive in brucellosis cases (8-10). They can be normal or slightly elevated. In our study, ESH elevation was detected at a rate of 43% and CRP elevation at a rate of 50.8%.

Brucella infections may manifest with specific organ involvement beside or without acute systemic symptoms. The liver is frequently involved in brucellosis. Liver enzymes usually show slight elevation. Studies have demonstrated transaminase elevation and hepatitis at a rate of 18.3-55% and 2.7-33.3%, respectively (6,13,14). In our study, transaminase elevation was at a rate of 37.5% and hepatitis at a rate of 23.5%. These findings were consistent with those of the literature. The most common local disease caused by Brucella spp is osteoarticular involvement. In the literature, osteoarticular involvement is seen in 20-85% of the cases (15-16). While joint pain was found in 38.5% of our cases, additional findings suggestive of arthritis such as joint swelling and limited joint movement were found in 20% of the cases. Genitourinary complications are seen at a rate of 1-20% in brucellosis (16%). In a study conducted on children, epididymoorchitis has been reported at a rate of 5.3% (17). We did not find epididymoorchitis in our patients. Neurobrucellosis is rare in children. Involvement of the central nervous system is seen in approximately 1% of the cases (18). We detected neurobrucellosis in 1 patient (1.5%) presenting with deviation of the eyes inwards, and this rate was consistent with the literature.

Zoonotic diseases like brucellosis may be more common among individuals sharing the same socio-economic conditions (19). In endemic regions, brucellosis cases have been reported in individuals of the same family (20). In a study by Roushan et al. including 469 cases, the rate of brucellosis in family members has been found as 9.6% (21). In a study by Çiftdoğan et al., brucellosis prevalence in index cases has been detected as 36.8% (9). In a study by Gündeslioglu including 145 cases, this rate has been confirmed as 39.2% in family members (7). In studies conducted on close-contact family members in the literature, seropositivity rates for brucella ranged between 2.9-39.2% (7,22-24). In our study, brucella seropositivity (36.9%) was detected in 9 close-contact family members of 24 index cases in whom family screening was performed. STA test was positive for Brucella in 18 (18.2%) of 99 close-contact family members of a total of 9 index cases. This rate varies in the literature. It is considered to be detected at a higher rate in endemic regions, and active brucellosis history in the family or immediate circle is important in diagnosis. Therefore, close-contact screening based on acute brucella cases found in a region may enable the detection of new cases.

To conclude, questioning family history in patients presenting due to fever, hepatosplenomegaly, pancytopenia or bicytopenia in our region and farming/husbandry and consumption of raw milk and raw dairy products is important in terms of early diagnosis. Clinical and serologic investigation of close family members of the patients diagnosed with brucellosis may enable the early diagnosis and treatment of close-contact cases. Screening wide contact groups in an endemic country like ours is important in terms of early diagnosis and treatment.

**Ethics Committe Approval:** The approval for this study was obtained from Çukurova University Faculty of Medicine Ethics Committee.

**Informed Consent:** Patient consent was obtained.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - EK, FÇÖ; Design - ÜÇ; Supervision - EK, ÖOG; Resource - EK, FÇÖ; Data Collection and/or Processing - FÇÖ, ÖOG; Analysis and/or Interpretation - IÜ, EK; Literature Search - FÇÖ, ÜÇ; Writing - FÇÖ, EK; Critical Review - ÜÇ, EK.

**Conflict of Interest:** All authors declare that they have no conflicts of interest or funding to disclose.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**

1. Sözen TH. Bruselloz. In: Willke Topçu A, Söyletir G, Doğanay M (eds). İnfeksiyon Hastalıkları ve Mikrobiyolojisi. Ankara: Nobel Tıp Kitabevleri, 2002:636-42. [CrossRef]

2. Edward JY. Brucella species. In: Mandell GL, Douglas RG, Bennet JE (eds). Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:2386-93. [CrossRef]

3. Eduardo G, Carlos C. Brucella. In: Gorbach SL, Barlett JG, Blacklow NR (eds). Infectious Diseases. 2nd ed. Philadelphia: W.B. Saunders Company, 1998:1837-45. [CrossRef]
4. Jennings GJ, Hajjeh RA, Girgis FY, Fadeel MA, Maksoud MA, Wasfy MO, et al. Brucellosis as a cause of acute febrile illness in Egypt. Trans R Soc Trop Med Hyg 2007;101:707. [CrossRef]

5. Saçar S, Cenger Hırcın D, Toprak S, Demir M, Turgut H. Otuz bruseloz olgusunun klinik değerlendirilmesi. Turk J Infect 2008;22(1):11-14. [CrossRef]

6. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, Akdeniz H. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010;14:469-78. [CrossRef]

7. Gündeşlioğlu ÖÖ. Brucella infection in children: Evaluation of 148 pediatric patients. J Clin Anal Med 2019;10(1):99-103. [CrossRef]

8. Yoldaş T, Tezer H, Parlakay AO, Saylı TR. Clinical and laboratory findings of 97 pediatric brucellosis patients in central Turkey. J Microbiol Immun Infect 2015;48:446-9. [CrossRef]

9. Çiftdoğan DY, Aslan S. Unrecognized pediatric and adult family members of children with acute brucellosis. Braz J Infect Dis 2017;21:520-4. [CrossRef]

10. Doğanay M, Alp Meşe E. Bruseloz. In: Willke Topçu A, Söyletir G, Doğanay M (eds). İnfeksiyon Hastalıkları ve Mikrobiyolojisi. 3. Baskı, Ankara: Nobel Tip Kitabevleri, 2008. [CrossRef]

11. Hasanjani Roushan MR, Mohrez M, Smallnejad Gangi SM, Solemani Amiri MJ, Hajijahmadi M. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect 2004;132:1109-14. [CrossRef]

12. Yüce A, Alp-Çavuş Ş. Türkiye’de Bruseloz: Genel bakış. Klinik 2006;19(3):87-97. [CrossRef]

13. Tanir G, Tufekci SB, Tuygun N. Presentation, complication, and treatment outcome of brucellosis in Turkish children. Pediatr Int 2009;51:114-9. [CrossRef]